Clinical trials in NSCLC have shown that bone metastasis is very common in non-small cell lung cancer; one clinical trial confirmed that 50%-60% of NSCLC tumor tissues express RANKL and RANK, and the trial showed that denosumab can directly block RANKL to inhibit bone metastasis in NSCLC. Here, TNFRSF11A is linked to neoplasm.